← Eichor
Condition: Ivosidenib Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ivosidenib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelod
Phase 3 · 62 location(s) · Institut de Recherches Internationales Servier · NCT06465953OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
Phase N/A · 21 location(s) · French Innovative Leukemia Organisation · NCT06377579Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treat
Phase 3 · 114 location(s) · Servier Bio-Innovation LLC · NCT06127407a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07007949Ivosidenib as Post-HSCT Maintenance for AML
Phase 2 · 6 location(s) · Massachusetts General Hospital · NCT06707493Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta
Phase 1/Phase 2 · 38 location(s) · Institut de Recherches Internationales Servier · NCT06501625Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Ref
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04774393Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06611839An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Phase 3 · 84 location(s) · Servier Affaires Médicales · NCT05876754Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Phase 1 · 30 location(s) · Institut de Recherches Internationales Servier · NCT02074839Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
Phase 2 · 12 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT07260175Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemi
Phase N/A · 13 location(s) · iOMEDICO AG · NCT06607302A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07392242Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML
Phase 3 · 119 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT07075016Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M
Phase 2 · 12 location(s) · Technische Universität Dresden · NCT06717958Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
Phase 1 · 1 location(s) · University of Chicago · NCT06291987A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
Phase 1 · 19 location(s) · Servier Bio-Innovation LLC · NCT07006688CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04493164Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for t
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05010772An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m
Phase 3 · 15 location(s) · Servier Affaires Médicales · NCT05907057An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07282262A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05756777Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07607418Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Phase 1/Phase 2 · 4 location(s) · M.D. Anderson Cancer Center · NCT03471260
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.